Form 13-F position report

IRONWOOD PHARMACEUTICALS IN

Reported by CAPSTONE INVESTMENT ADVISORS LLC

IRWD 0.75 06/15/24 CUSIP 46333XAF5 Manager CIK 0001426196

First reported at 0 shares this quarter.

Reported value -100.0%; share count 0.0% vs. the prior quarter.

Unchanged
% of reported 13F value 0 This manager · Q2 2024
Shares 0 Quarter-end amount reported
Reported value $0 Fair value at quarter end
Consecutive quarters held 16 Through Q2 2024

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 10870000
2022-03-31 14624000
2022-06-30 18674000
2022-09-30 22913000
2022-12-31 24473438
2023-03-31 32589833
2023-06-30 40617120
2023-09-30 39922620
2023-12-31 50204252
2024-03-31 51538438
2024-06-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

11 quarters
Quarterly reported position history for IRONWOOD PHARMACEUTICALS IN held by CAPSTONE INVESTMENT ADVISORS LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q2 2024 Unchanged 0 0 (0.0%) 0 $0 2024-08-14
Q1 2024 Unchanged 0 0 (0.0%) 0.19% $51,538,438 2024-05-01
Q4 2023 Reduced 0 -40,200,000 (-100.0%) 0.15% $50,204,252 2024-02-12
Q3 2023 Unchanged 40,200,000 0 (0.0%) 0.18% $39,922,620 2023-11-13
Q2 2023 Added 40,200,000 +8,000,000 (24.8%) 0.2% $40,617,120 2023-08-10
Q1 2023 Added 32,200,000 +9,500,000 (41.9%) 0.16% $32,589,833 2023-05-09
Q4 2022 Unchanged 22,700,000 0 (0.0%) 0.18% $24,473,438 2023-02-10
Q3 2022 Added 22,700,000 +5,000,000 (28.2%) 0.14% $22,913,000 2022-11-10
Q2 2022 Added 17,700,000 +5,000,000 (39.4%) 0.09% $18,674,000 2022-08-15
Q1 2022 Added 12,700,000 +3,000,000 (30.9%) 0.04% $14,624,000 2022-05-13
Q4 2021 Unchanged 9,700,000 0 (0.0%) 0.02% $10,870,000 2022-02-11
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

18 managers reported IRONWOOD PHARMACEUTICALS IN for Q2 2024.

Managers reporting IRONWOOD PHARMACEUTICALS IN in Q2 2024.
Manager Activity Shares Change % of reported 13F Reported value Tenure
WELLS FARGO & COMPANY MN Reduced 0 -2,000,000 0 $0 2 qtrs
BANK OF MONTREAL Reduced 0 -8,500,000 0 $0 5 qtrs
Citigroup Inc Reduced 0 -2,352,000 0 $0 14 qtrs
CAPSTONE INVESTMENT ADVISORS LLC This report Unchanged 0 0 0 $0 16 qtrs
TENOR CAPITAL MANAGEMENT Co L P Reduced 0 -37,375,000 0 $0 16 qtrs
LAZARD ASSET MANAGEMENT LLC Reduced 0 -18,738,000 0 $0 2 qtrs
GROUPAMA ASSET MANAGMENT Reduced 0 -1,000,000 0 $0 2 qtrs
CONCOURSE FINANCIAL GROUP SECURITIES INC Unchanged 0 0 0 $0 16 qtrs
Calamos Advisors LLC Reduced 0 -5,000 0 $0 16 qtrs
Virtus Investment Advisers Inc Reduced 0 -42,000 0 $0 3 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2024
Filed
August 14, 2024
Filing type
13F-HR
Position type
NOTE 0.750% 6/1

Voting authority reported

No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.